Title: Impact of Scabies on Quality of Life and Recent Advances in **Management: A Systematic Review** 

#### **Authors:**

Sakshi Kumari, Swathi Srinivas, Zainab Siddiqua, Muhammad Saeed Qazi, Mahin Sheikh, Shree Rath, Maham Khan, Muhammad Daim Jawaid, Nayanika Tummala, Madho Mal.

Affiliation: Shimoga Institute of Medical Sciences, Shimoga, India, Sri Ramachandra Institute of Higher Education and Research, Chennai, India, Gandhi Medical College, Secunderabad, India, Bilawal Medical College, Jamshoro, Pakistan, Ameer-ud-Din Medical College, Lahore General Hospital, Lahore, Pakistan, All India Institute of Medical Sciences, Bhubaneswar, India, Fatima Jinnah Medical University, Lahore, Pakistan, Rashid Latif Medical College, Lahore, Pakistan, GITAM Institute of Medical Sciences and Research, Secunderabad, India, Liaguat University of Medical and Health Science Jamshoro

#### **Abstract**

**Introduction:** Scabies are a highly transmittable disease of the skin. It is caused by a specific mite named Sarcoptes scabiei. Individuals who are infected with scabies have a miserable life, and their quality of life is poor. It impacts the quality of life by causing physical discomfort due to itching. Not only does it lead to the mental distress of a diseased individual, but it also leads to social isolation due to the stigma associated with this condition. This systematic review highlights the profound effect of scabies on the lives of affected individuals and the recent breakthroughs in the management of scabies.

**Purpose:** The purpose of this article is to shed light on the impact of scabies on the quality of life. We also discussed the advancements in the management of this disease, which impacts life physically and socially.

**Method:** We included randomized controlled trials, clinical trials, and observational studies. Studies with full-text access were included. Case reports, letters, and systematic/narrative reviews were excluded from the search. 180 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. I COTAS WEIE SCIENTED UP TO INTEREST.

PubMed and 51 from Google Scholar. 22 articles were thoroughly screened by two different reviewers independently and included in the review. Studies were carried out with no restrictions on age or sex, including the pediatric and adult populations.

**Conclusion:** Findings indicate a significant correlation between scabies and poor quality of life. Scabies most commonly affect children of lower socioeconomic status and in resource-limited settings. Scabies can lead to severe complications such as rheumatic heart disease, kidney diseases, and a variety of secondary bacterial infections; therefore, advances in treatment strategies are needed. Currently, permethrin and ivermectin have been used for treatment. Moxidectin, a new drug, is undergoing clinical trials to replace permethrin in regions with high resistance. The interventions need to be patientcentered, and new drugs need to be developed that have anti-parasitic actions and also lead to the prevention of secondary bacterial infections.

**Keywords:** scabies, quality of life, psychology, and management.

### Introduction

The infectious disease scabies is brought on by an infestation of the obligatory human parasite, Sarcoptes scabiei. Skin-to-skin contact, including intercourse, or, less frequently, contact with contaminated fabrics (such as clothes and towels), can result in the infestation. Less than 5 to 15 mites per host are present in classical scabies. Crusted scabies are typified by an extremely elevated mite burden in the afflicted person (1). It is typically seen occasionally as an institutional outbreak in hospitals, schools, retirement communities, and longterm care facilities in industrialized countries. Its incidence in underdeveloped urban and rural areas may approach 10% in the overall population and 60% in children (2). Around 300 million cases of scabies are reported annually, with a significant concentration of infections in Southeast Asia. Scabies is the sixth most prevalent skin condition in some locations, and summertime is when most instances are reported. (3)

Scabies were found to be the cause of 0.21% of disability-adjusted life years globally across all conditions examined by the Global Burden of Disease 2015 study. As a result, the degree of clinical pathology and the psychological effects of the disease may both have an impact on scabies morbidity. Furthermore,

because of the disease's rising incidence and resistance to therapy, scabies may worsen patients' quality of life (QoL). QoL is affected by scabies to a moderateto-severe degree. Depressive and anxiety scores are positively correlated with impaired QoL. (4) Nevertheless, Prompt management of scabies can avert sequelae like acute rheumatic fever and acute post-streptococcal glomerulonephritis, as well as secondary pyoderma. Scabies significantly lower a patient's quality of life. (3)

A comparison study conducted in Fiji showed that ivermectin outperforms permethrin. When azithromycin and ivermectin were taken together, however, the incidence of impetigo and scabies decreased just as much as when ivermectin was taken alone. After mass medication administration, the percentage of impetigo lesions containing pyogenic streptococci decreased. After the azithromycin mass drug administration, there was a brief rise in the percentage of S. aureus bacteria that were resistant to macrolides. (5)

The typical method for diagnosing scabies involves identifying the mite, eggs, or excrement through microscopic analysis of scales that are removed from the skin by scraping. The adhesive tape test and the burrow ink test are two further diagnostic techniques. Some sophisticated non-invasive methods, including optical coherence tomography, dermatoscopy, in vivo reflectance confocal microscopy, and video dermatoscopy, have shown increased efficacy in the diagnosis of scabies in recent years (2).

A study shows At the 4-week mark, Ivermectin had a cure rate of 78.5% with a single dose, whereas 59.5% of patients responded well to a single treatment of 10% sulfur ointment. At the 2-week follow-up, a single ivermectin dose was just as effective as a single application of sulfur 10% ointment. At the 4-week follow-up, ivermectin was better than sulfur 10% ointment after the treatment was repeated. Ivermectin's delayed clinical response raises the possibility that it is ineffective against all phases of the parasite's life cycle. Another study shows that at the 2-week follow-up, two treatments of ivermectin were just as effective as two applications of permethrin 2.5% cream. At the 4-week follow-up, ivermectin was just as effective as permethrin 2.5% cream after the treatment was repeated. (6,7)

Although permethrin has a higher treatment cost per case, it can offer a considerable efficacy of 88% and acceptance in 100% of instances. Ivermectin is less expensive and has efficacy and acceptance rates of 84% and 96%, respectively. Benzyl benzoate was the least expensive medication and delivered

80% for both rates. The least effective and most costly product was sulfur ointment. (8)

This comprehensive systematic review emphasizes the significant impact scabies have on afflicted people's lives as well as the most current advancements in scabies treatment.

This article's goal is to evaluate how scabies affect quality of life and discuss recent advancements in their management. We also examined its nature, its impact on well-being, optimal medications, their effectiveness, and strategies to decrease its prevalence.

## **Objectives**

To assess the impact of scabies on quality of life and recent advances in management

# **Methodology:**

# **Aims and Objectives:**

"What is the impact of scabies infection on the quality of life, and what are recent advancements made in the management of this disease?

Table. 1; Selection Criteria

Population	Patients with risk factors, physical symptoms, and stigma
	associated with scabies
Intervention	Recent advancements in the management of scabies
Comparison	Comparison with previously available treatment options
Outcome	Impact on the Quality of life of patients
Study Design	RCT and clinical Trials

## **Search Strategy:**

PubMed was searched using a combination of keywords "Scabies, Quality of life/Psychology and Management", and included interventions to identify planned, ongoing, terminated, and completed RCTs and Clinical trials. Full-text publications were retrieved from 2014 - 2024. If no full-text publications were found Google Scholar was also searched to retrieve full texts. Following is the full PubMed search strategy, which is modified for the Cochrane Database.

# Scabies and QOL without Cochrane trial filter

Scabies [tw] OR "Sarcoptes scabiei" [tw] OR "Mange, Sarcoptic" [tw] OR "Sarcoptic Mange" [tw] OR Scabies [mh] AND ("Quality of life" [tw] OR Stigma [tw] OR "Psychological wellbeing" [tw] OR "Patient satisfaction" [tw] OR "Psychological resilience" [tw] OR "Life Quality" [tw] OR "Health-Related Quality Of Life" [tw] OR "Health-Related Quality Of Life" [tw] OR HRQOL OR "Life Styles" [tw] OR Lifestyle\* [tw] OR "Lifestyle Induced Illness" [tw] OR "Lifestyle Factors" [tw] OR "Value of Life" [tw] OR "Quality of Life/psychology" [mh])

## Scabies and Management with Cochrane Trial Filter

((Scabies [tw] OR "Sarcoptes scabiei" [tw] OR "Mange, Sarcoptic" [tw] OR "Sarcoptic Mange" [tw] OR Scabies [mh]) AND (Treatment\* [tw] OR Diagnos\* [tw] OR Strateg\* [tw] OR "Disease Management\*" [tw] OR Manag\* [tw] OR Advancement\* [tw] OR "Management, Disease" [tw] OR "Disease Management" [mh])) AND (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab] OR animals [mh] NOT humans [mh])

# **Cochrane Central Search Strategy:**

- #1 MeSH descriptor: [Scabies] explode all trees
- #2 (Scabies): ti,ab,kw (Word variations have been searched)
- #3 (Sarcoptes scabiei): ti,ab,kw (Word variations have been searched)
- #4 (Mange, Sarcoptic): ti,ab,kw (Word variations have been searched)
- #5 (Sarcoptic Mange): ti,ab,kw (Word variations have been searched)
- #6 #1 OR #2 OR #3 OR #4 OR #5
- #7 MeSH descriptor: [Disease Management] explode all trees
- #8 (Treatment): ti,ab,kw (Word variations have been searched)
- #9 (Diagnosis): ti,ab,kw (Word variations have been searched)
- #10 (strategies): ti,ab,kw (Word variations have been searched)

- #11 (advancement): ti,ab,kw (Word variations have been searched)
- #12 #7 OR #8 OR #9 OR #10 OR #11
- #13 #6 AND #12
- #14 MeSH descriptor: [Quality of Life] explode all trees
- #15 (Stigma): ti,ab,kw (Word variations have been searched)
- #16 (Quality of life): ti,ab,kw (Word variations have been searched)
- #17 (Psychological wellbeing): ti,ab,kw (Word variations have been searched)
- #18 (Patient satisfaction): ti,ab,kw (Word variations have been searched)
- #19 (Psychological resilience): ti,ab,kw (Word variations have been searched)
- #20 (Life Quality): ti,ab,kw (Word variations have been searched)
- (Health-Related Quality of Life): ti,ab,kw (Word variations have been #21 searched)
- #22 (Value of Life): ti,ab,kw (Word variations have been searched)
- #23 #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
- #24 #6 AND #23

### **Eligibility Criteria:**

- 1. RCT, Clinical Trials, and Observational studies are included
- 2. Studies conducted between 2014 2024.
- 3. Studies were carried out with no restrictions on age and sex including the pediatric and adult population.
- 4. Studies report recent advancements in the diagnosis, understanding, and treatment of scabies.
- 5. Studies exploring prevalence, risk factors, stigma, and physical symptoms associated with scabies.
- 6. Studies focusing on the impact of scabies infection on quality of life.

- 7. This review did not include case reports, letters to editors, reviews, and case series.
- 8. Articles in languages other than English are also excluded from the review.

# **Screening and Selection:**

The bibliographic database was managed through Mendeley. Two independent reviewers initially assessed the paper based on its title and abstract. Case reports, letters, and systematic/narrative reviews were excluded from the search. Papers containing relevant keywords in their titles and abstracts were chosen for full-text review. If a paper lacked an abstract but its title related to the review's objectives, it was also considered for full-text screening. Both reviewers undertook a detailed examination of the selected full-text papers. Those meeting all selection criteria were then subjected to data extraction. Additionally, the reviewers manually examined the reference lists of all selected articles to find any further relevant papers. Any disagreements between the reviewers were resolved through discussion.

# **Data Extraction and Quality Assessment**

Data extraction was done by one reviewer using a standardized form and was verified by another reviewer. The study was assessed based on study design, participants' demographics, intervention, outcome measures, and safety profile. The quality assessment process was conducted by an independent reviewer and validated by a second reviewer through RevMan. For RCT, ROB2 was used. Disagreements for each criterion were settled through discussion.

One significant challenge during the data collection process was the unavailability of free full-text articles for many studies. This limitation hindered our access to comprehensive data, as we relied on complete texts to extract relevant information. Additionally, several studies were not available in English, which further restricted our access to crucial data. The language barrier prevented us from including potentially valuable studies in our analysis.

Another obstacle we faced was encountering studies with incomplete or insufficient data. Some studies lacked proper documentation of their

methodology, making it difficult to assess the reliability and validity of their findings. Without a clear understanding of the study methodology, we were unable to incorporate these studies into our analysis with confidence.

Study findings included in the study are summarised below:

Authors and year	Country	Stud y Desig	intervention	Institution	Outcome Measures	Safety Profile	Part icip ants	Significant Findings
Meyersbur g et al 2024	Austria	n RCT	The study highlights the reduced efficacy of topical permethrin 5% in treating scabies, possibly due to increasing mite resistance. BB 25% demonstrate d a significantly higher cure rate and reasonable tolerability despite the reported burning sensation.	University Hospital Salzburg of the Paracelsus Medical University Salzburg, Salzburg, AustriA	Treatment efficacy was assessed based on dermoscopy- verified cure rates at a 3-week follow-up visit. Tolerability and safety profiles of both topical permethrin 5% and BB 25% were evaluated, focusing on adverse reactions and patient- reported symptoms.	Permethrin 5% cream demonstrated excellent tolerability and safety, with minimal adverse effects reported. BB 25% emulsion, on the other hand, produced a burning sensation in 43% of patients, indicating lower tolerability compared to permethrin.	110	The study compared the efficacy of topical permethrin 5% and benzyl benzoate (BB) 25% in treating scabies. Dermoscopy-verified cure rates at a 3-week follow-up were 27% in the permethrin group and 87% in the BB group. Permethrin demonstrated a lack of efficacy in the majority of scabies cases, whereas BB showed a significantly higher cure rate.
Hardy et al 2021	Republic of Fiji	RCT	The findings suggest that implementin g a 1-dose ivermectin-based Mass Drug Administration (MDA) could be as effective as the traditional 2-dose regimen	Murdoch Childrenâ €™s Research Institute, Melbourn e, Victoria, Australia	Scabies prevalence was the primary outcome measure, assessed at baseline and 12 months post- intervention. The study also evaluated the effectiveness of different MDA strategies (2-	headache, dizziness, nausea, diarrhea, or abdominal discomfort. Neurological symptoms: Rarely, ivermectin can cause neurological adverse effects like	381 2	The study compared the effectiveness of different community-wide treatment strategies for controlling scabies prevalence in Fijian villages.  Both the 2-dose ivermectin-based Mass Drug Administration (MDA) and 1-dose ivermectin-based MDA, as well as a screen-and-

			for controlling scabies at the community level. A screenand-treat strategy using topical permethrin also showed substantial reductions in scabies prevalence.		dose vs. 1-dose ivermectin-based MDA) and a screen-and-treat approach with topical permethrin in reducing community-level scabies burden.	drowsiness, tremors, or confusion, especially at higher doses.		treat approach with permethrin, substantially reduced scabies prevalence at 12 months. The 1-dose ivermectin-based MDA was found to be non-inferior to the 2-dose regimen in terms of reducing scabies prevalence in the community.
Alipour et al 2015	Iran	RCT		Tabriz university of medical scien	oral ivermectin showed higher efficacy with cure rates of 61.9% after a single dose at 2 weeks and 78.5% after repeated treatments at 4 weeks. Sulfur ointment achieved lower cure rates initially (45.2% at 2 weeks, improving to 59.5% at 4 weeks with repeated applications)	Both treatments were well-tolerated, with mild irritation being the main reported adverse event.	420	Oral ivermectin demonstrated superior and sustained clearance of scabies lesions compared to sulfur ointment, highlighting its effectiveness as an alternative treatment option for scabies
Marina et al 2022	Indonesi a	RCT		1 Dermatol ogy and Venereolo gy Departme nt, Faculty of Medicine, Universita s Indonesia â€" Dr Cipto Mangunk usumo General				

			Hospital,			
			Jakarta,			
			IndonesIa			
Romani et	Solomo	Rct	The Kirby	Outcome	261	After mass drug
al 2019	n		Institute,	measures	88	administration, scabies
	islands		UNSW,	included		prevalence reduced by
			Sydney,	comparing		88% (95% CI
			NSW,	scabies and		76.5–99.3) and
			Australia	impetigo		impetigo by 74%
				prevalence in ten		(63.4–84.7) at 12
				randomly		months. Outpatient
				selected villages		clinic attendance
				at 12 months		decreased by 36.1%
				versus baseline		(95% CI 34.7–37.6)
				to ensure		overall and by 50.9%
				representativene		(95% CI 48.6–53.1)
				ss. Additionally,		for skin sores, boils,
				outpatient clinic		and abscesses.
				attendance for		Integrating ivermectin-
				any reason was		based treatment with
				analyzed in the 3		azithromycin for
				months post-		trachoma achieved
				mass drug		high efficacy,
				administration		supporting population-
				compared to the		level control strategies
				pre-		
				administration		
				period (excluding		
				the		
				administration		
				month). Further		
				comparisons		
				included clinic		
				attendance		
				before and after		
				administration		
				within shorter (1		
				month) and		
				longer (12		
				months) time		
				frames, excluding		
				the		
				administration		
				month. Finally,		
				paired analyses		
				of scabies and		
				impetigo		
				prevalence were		
				conducted in		
				four baseline		
				villages at 12		

					months, and			
					baseline			
Illyas et al	Pakistan	RCT		Fatima	The primary	Common	60	Efficacy Comparison:
2023				Jinnah	outcome	adverse		Permethrin 5%
				Medical	measures	events		demonstrated higher
				University	included clinical	associated		efficacy compared to
				, LahorE	grading of	with oral		oral ivermectin in
					scabies lesions	ivermectin		treating scabies, with
					and itch severity	may include		73.3% of patients
					scores. Efficacy	gastrointestin		showing efficacy in the
					was assessed	al symptoms		permethrin group
					based on the	(such as		versus 26.7% in the
					proportion of	nausea,		ivermectin group (p-
					patients showing	vomiting,		value < 0.05).
					improvement in	diarrhea),		Age Distribution: The
					symptoms and	dizziness, and		mean age of patients
					resolution of	skin reactions.		receiving permethrin
					scabies lesions	Topical		was slightly higher than
					after one week of	permethrin		those receiving
					treatment.	can		ivermectin, but this
						sometimes		difference did not
						cause local		impact the efficacy
						skin irritation		outcomes significantly.
						or allergic		
						reaction		
Susanna J.	Solomo	Clust	20 villages	Tropical	The primary	Pregnant	20	There was no reduction
Lake et al	n	er	randomly	Diseases	outcome	women,	villa	in scabies prevalence
2018	Islands	RCT	assigned to	Research	measure of this	young	ges	in either the one or
			receive	Group,	trial was the	children, and		two dose arms.
			either one	Murdoch	change in scabies	individuals		However there was a
			dose (Arm 1)	Childrenâ	prevalence at 12	with specific		reduction in the
			or two doses	€™S	months post-	contraindicati		severity of scabies
			7–14 days	Research	Mass Drug	ons received		
				1	A al	4		
			apart (Arm 2)	Institute,	Administration	topical		
			of Mass Drug	Melbourn	(MDA) compared	permethrin		
			of Mass Drug Administratio	Melbourn e,	(MDA) compared to baseline (pre-	permethrin instead.		
			of Mass Drug	Melbourn e, Australia,	(MDA) compared to baseline (pre- MDA). Secondary	permethrin instead. Adverse		
			of Mass Drug Administratio	Melbourn e, Australia, 2	(MDA) compared to baseline (pre- MDA). Secondary outcome	permethrin instead. Adverse effects such as		
			of Mass Drug Administratio	Melbourn e, Australia, 2 Departme	(MDA) compared to baseline (pre- MDA). Secondary outcome measures	permethrin instead. Adverse effects such as gastrointestin		
			of Mass Drug Administratio	Melbourn e, Australia, 2 Departme nt of	(MDA) compared to baseline (pre- MDA). Secondary outcome measures included scabies	permethrin instead. Adverse effects such as gastrointestin al symptoms,		
			of Mass Drug Administratio	Melbourn e, Australia, 2 Departme nt of Paediatric	(MDA) compared to baseline (pre- MDA). Secondary outcome measures included scabies prevalence at 24	permethrin instead. Adverse effects such as gastrointestin al symptoms, dizziness, and		
			of Mass Drug Administratio	Melbourn e, Australia, 2 Departme nt of Paediatric s,	(MDA) compared to baseline (pre-MDA). Secondary outcome measures included scabies prevalence at 24 months post-	permethrin instead. Adverse effects such as gastrointestin al symptoms, dizziness, and skin reactions		
			of Mass Drug Administratio	Melbourn e, Australia, 2 Departme nt of Paediatric s, University	(MDA) compared to baseline (pre-MDA). Secondary outcome measures included scabies prevalence at 24 months post-MDA, as well as	permethrin instead. Adverse effects such as gastrointestin al symptoms, dizziness, and skin reactions were		
			of Mass Drug Administratio	Melbourn e, Australia, 2 Departme nt of Paediatric s, University of	(MDA) compared to baseline (pre-MDA). Secondary outcome measures included scabies prevalence at 24 months post-MDA, as well as prevalence rates	permethrin instead. Adverse effects such as gastrointestin al symptoms, dizziness, and skin reactions were monitored		
			of Mass Drug Administratio	Melbourn e, Australia, 2 Departme nt of Paediatric s, University of Melbourn	(MDA) compared to baseline (pre-MDA). Secondary outcome measures included scabies prevalence at 24 months post-MDA, as well as prevalence rates of impetigo (a	permethrin instead. Adverse effects such as gastrointestin al symptoms, dizziness, and skin reactions were monitored and managed		
			of Mass Drug Administratio	Melbourn e, Australia, 2 Departme nt of Paediatric s, University of Melbourn e,	(MDA) compared to baseline (pre-MDA). Secondary outcome measures included scabies prevalence at 24 months post-MDA, as well as prevalence rates of impetigo (a bacterial skin	permethrin instead. Adverse effects such as gastrointestin al symptoms, dizziness, and skin reactions were monitored and managed by healthcare		
			of Mass Drug Administratio	Melbourn e, Australia, 2 Departme nt of Paediatric s, University of Melbourn e, Melbourn	(MDA) compared to baseline (pre-MDA). Secondary outcome measures included scabies prevalence at 24 months post-MDA, as well as prevalence rates of impetigo (a bacterial skin infection often	permethrin instead. Adverse effects such as gastrointestin al symptoms, dizziness, and skin reactions were monitored and managed		
			of Mass Drug Administratio	Melbourn e, Australia, 2 Departme nt of Paediatric s, University of Melbourn e, Melbourn e,	(MDA) compared to baseline (pre-MDA). Secondary outcome measures included scabies prevalence at 24 months post-MDA, as well as prevalence rates of impetigo (a bacterial skin infection often coexisting with	permethrin instead. Adverse effects such as gastrointestin al symptoms, dizziness, and skin reactions were monitored and managed by healthcare		
			of Mass Drug Administratio	Melbourn e, Australia, 2 Departme nt of Paediatric s, University of Melbourn e, Melbourn e, Australia,	(MDA) compared to baseline (pre-MDA). Secondary outcome measures included scabies prevalence at 24 months post-MDA, as well as prevalence rates of impetigo (a bacterial skin infection often coexisting with scabies) at the	permethrin instead. Adverse effects such as gastrointestin al symptoms, dizziness, and skin reactions were monitored and managed by healthcare		
			of Mass Drug Administratio	Melbourn e, Australia, 2 Departme nt of Paediatric s, University of Melbourn e, Melbourn e,	(MDA) compared to baseline (pre-MDA). Secondary outcome measures included scabies prevalence at 24 months post-MDA, as well as prevalence rates of impetigo (a bacterial skin infection often coexisting with	permethrin instead. Adverse effects such as gastrointestin al symptoms, dizziness, and skin reactions were monitored and managed by healthcare		

Matthewm an et al 2020	Gabon	RCT	Treating all family members and close contacts of individuals with scabies is a common	e Childrenâ €™s Global Health, Melbourn e, Australia	Primary Endpoint: Clinical cure after 28 days. Secondary Endpoint: Proportion of affected	•	79	The study investigated the effectiveness of treating all family members and close contacts of individuals with scabies, compared to treating only the affected individuals. It
			approach recommende d to prevent disease spread, but the evidence supporting this practice is limited.		household members per household after 28 days.			found that treating household contacts alongside affected individuals may lead to improved clinical cure rates and reduced scabies prevalence within households. However, the observed benefit was less pronounced than anticipated, suggesting the need for further research to definitively evaluate this practice.
Lake et al 2020	Solomo n	RCT	The RISE trial aims to	•	The primary outcome		20 villa	primary objective of the RISE trial is to
	Islands		address the challenges		measure is the reduction in		ges	determine if ivermectin-based mass
			associated		scabies			drug administration
			with		prevalence after			(MDA) with one dose is
			implementin		12 months,			as effective as MDA
			g two-dose		comparing one-			with two doses in
			ivermectin- based MDA		dose MDA to two-dose MDA.			reducing the prevalence of scabies
			for scabies		Secondary			after 12 months.
			control in		outcome			Secondary objectives
			resource-		measures include			include assessing the
			limited		impetigo			impact on impetigo
			settings. If		prevalence after			prevalence after 12
			the trial		12 and 24			and 24 months, scabies
			demonstrate		months, scabies			prevalence at 24
			s non-		prevalence at 24			months post-
			inferiority of		months post-			intervention, and the
			one-dose		intervention, and			impact on healthcare

			MDA compared to two doses, this could significantly simplify and streamline scabies control programs, particularly in high- prevalence areas like the Solomon Islands.	the impact on healthcare facility visits related to scabies and impetigo.			facility presentations with scabies and impetigo.
Sungkar et al 2014	Indonesi	RCT	The findings suggest that standard whole-body permethrin treatment for scabies is as effective as a modified approach limited to lesion-only application followed by bathing with soap. While the differences in cure rates were not statistically significant, the recurrence rate was lower with standard treatment. Further research with larger sample sizes may be needed to confirm these results.	The primary outcome measures were the cure rates and recurrence rates of scabies after three weeks of treatment. These rates were compared across the three treatment groups to determine the effectiveness of each approach.	permethrin is known to cause side effects such as erythema, pain, itching, and prickling sensation when applied all over the body.	69	The study compared the effectiveness of standard whole-body permethrin treatment for scabies against a modified approach limited to lesion-only application followed by bathing with regular or antiseptic soap. The cure rates after three weeks were 95.7% for standard treatment, 91.3% for lesion-only with regular soap, and 78.3% for lesion-only with antiseptic soap. Recurrence rates were 8.7% for standard treatment, 13% for lesion-only with regular soap, and 26.1% for lesion-only with antiseptic soap.

		<del> </del>				<del>-</del>		
Meyersbur g et al 2023		RCT	The study's findings suggest that both topical benzyl benzoate and oral ivermectin are effective first-line therapies for scabies treatment, with comparable therapeutic efficacy. For cases of initial treatment failure or recalcitrant and extensively infested cases, a combination of BB plus ivermectin may be considered for improved outcomes. The study highlights the importance of alternative treatments given the reported decreasing efficacy of standard 5% permethrin cream for	1Departm ent of Dermatol ogy and Allergolog y, University Hospital Salzburg of the Paracelsus Medical University , Salzburg, Austria	Treatment outcome was assessed by dermoscopy at a 3-week follow-up visit. Cure rates and treatment response upon retreatment were primary outcome measures.	Oral ivermectin demonstrated an excellent safety profile with good tolerability. Topical benzyl benzoate (BB) caused short burning sensations in 14% of patients.	224	Both topical benzyl benzoate (BB) and oral ivermectin showed comparable therapeutic efficacy, with cure rates of 87% in the BB group and 86% in the ivermectin group. In cases of initial treatment failure, retreatment with either BB or ivermectin, and their combination, demonstrated improved treatment responses. The combination of BB plus ivermectin showed particularly high success rates upon retreatment.
			cream for scabies					
Behera et al 2021	India	RCT		Society for Education Action and Research	Patients diagnosed contacts received s with oral Ivermecti (intervention). In t villages), patients d	supervised treatm in in six villages the control arm (s	nent six	Results showed a significant reduction in the risk of scabies in villages where oral Ivermectin was used

				in	were referred to th	ne nearest clinic fo	or	compared to villages
				Communit	treatment with ski	n creams and		where skin creams
				y Health	lotions.(control)			were used:
				(SEARCH),				Risk reduction of 79%
				Gadchiroli				at two months post-
				,				treatment.
				Maharash				Risk reduction of 51%
				tra, India				at twelve months post-
								treatment.
Marks et al	Solomo	RCT	The study	1Clinical	Seroprevalence		129	The study conducted in
2020	n		highlights the	Research	of antibodies to		1	selected communities
	Islands		ancillary	Departme	NIE was			in the Solomon Islands
			benefits of	nt, Faculty	measured at			demonstrated a
			ivermectin	of	baseline and 12			decrease in
			MDA for	Infectious	months post-			seroprevalence of
			scabies	and	MDA to assess			antibodies to NIE
			control,	Tropical	the impact of			(indicative of S.
			demonstratin	Diseases,	ivermectin on S.			stercoralis exposure)
			g a reduction	London	stercoralis			one year after a single
			in S.	School of	exposure.			ivermectin Mass Drug
			stercoralis	Hygiene	Absolute and			Administration (MDA)
			seroprevalen	and	relative			aimed at scabies
			ce in addition	Tropical	reductions in			control.
			to its	Medicine,	seroprevalence			The overall reduction in
			intended	London,	were calculated			seroprevalence was
			impact.	United	to evaluate the			accompanied by
			The findings	Kingdom,	effectiveness of			decreases in median
			suggest		the MDA.			fluorescence intensity
			potential					against NIE, particularly
			synergies in					among children aged 5
			integrating					years or older who
			deworming					received ivermectin.
			programs					
			(e.g.,					
			albendazole)					
			with					
			ivermectin to					
			control					
			multiple					
			neglected					
			tropical					
			diseases					
			(NTDs)					
0.0		D.C.T.	concurrently.	461: : :	Th			<b>The state of the state</b>
Marks et al	•	RCT	The study	1Clinical	The primary	•	6	The study investigated
2019			highlights the	Research	outcomes		com	the impact of co-
			effectiveness	Departme	measured were		mun	administering
			of	nt, Faculty	scabies and		ities	azithromycin with
			ivermectin-	of	impetigo			ivermectin-based mass
			based MDA	Infectious	prevalence at			drug administration
			in reducing	and	baseline and	]		(MDA) on the

			scabies and impetigo prevalence. Co-administratio n of azithromycin did not provide additional benefits in terms of reducing prevalence but led to changes in the bacterial profile of impetigo lesions. The transient increase in macrolideresistant S. aureus strains following azithromycin MDA underscores the importance of antimicrobial	Tropical Diseases, London School of Hygiene & Tropical Medicine	after 12 months. Secondary outcomes included the proportion of impetigo lesions containing specific bacteria and the detection of antimicrobial resistance.			prevalence of scabies and impetigo. The results showed that both treatment arms (ivermectin-only and combined treatment) led to substantial reductions in scabies and impetigo prevalence after 12 months. The proportion of impetigo lesions containing pyogenic streptococci decreased significantly following MDA. However, there was a transient increase in the proportion of macrolide-resistant Staphylococcus aureus strains detected after azithromycin MDA.
Thomas et al 2018	Australi a	RCT	stewardship.				200	
Anissa et al 2022	Indonesi a	RCT	The study provides initial insights into the potential effectiveness of Blacksoap® as an adjunctive therapy for scabies treatment, although		Primary Outcome: Cure rate of scabies after 4 weeks of treatment. Secondary Outcomes: Pruritus VAS scores, TEWL scores, and assessment of side effects between the	The study did not report any significant adverse effects associated with the use of Blacksoap® as an adjunctive therapy for scabies treatment.	78	Cure Rate: The cure rate in the intervention group (receiving Blacksoap®) was lower than the control group in the first week (75% vs. 81%), but higher in the fourth week (97% vs. 92%). This indicates a potential delayed but more effective response to treatment with Blacksoap®.

further	intervention and	Pruritus VAS Scores:
research with	control groups.	There was no
larger sample		significant difference in
sizes and		pruritus Visual Analog
longer		Scale (VAS) scores
follow-up		between the
periods may		Blacksoap® group and
be needed to		the placebo group,
confirm		suggesting comparable
these		relief of itching with
findings.		both treatments.
The delayed		Transepidermal Water
but		Loss (TEWL) Scores:
ultimately		Similarly, TEWL scores
higher cure		did not significantly
rate		differ between the two
observed in		groups, indicating no
the		notable impact of
Blacksoap®		Blacksoap® on skin
group		barrier function
suggests that		compared to placebo.
the soap may		Side Effects: There
have a		were no considerable
beneficial		differences in reported
effect when		side effects between
used in		the Blacksoap® group
conjunction		and the placebo group,
with		suggesting similar
standard		safety profiles for both
permethrin		treatments.
cream		treatments.
therapy.		
The study's		
use of		
standardized		
outcome		
measures		
(pruritus VAS		
and TEWL)		
provides		
valuable		
objective		
data on		
symptom		
relief and		
skin barrier		
function,		
supporting		
the		
comparabilit		
y of		

Blackspapk* to placebo in terms of efficacy and safety. Non- parametric statistical analysis was employed due to the nature of the data, ensuring robust evaluation and interpretatio n of the valuation of the data, ensuring robust evaluation and interpretation of the data, ensuring robust evaluation and permethrin 5% are equally achieving a chieving a chieve of effects a chieve of effe

Shaheen et al 2017	Pakistan	adherence, patient preferences, and potential adverse effects should be considered when selecting the optimal treatment for individual patients.  The findings of this study support the use of combination therapy (topical and oral ivermectin) as a safe and effective treatment option for uncomplicate d scabies. The significant reduction in itching and lesion count observed with combination therapy highlights its potential benefits over permethrin and topical ivermectin alone.		Overall, the combination of topical and oral ivermectin was well-tolerated with fewer reported adverse events compared to permethrin and topical ivermectin alone.	236	The combination of topical and oral ivermectin demonstrated superior efficacy compared to permethrin and topical ivermectin alone. Reduction in Itching: By the first week, the combination treatment group experienced a significant reduction in severity of itching (77.6%) compared to topical ivermectin (61.8%) and permethrin (8.3%). Decrease in Lesions: Similarly, the combination treatment group showed a notable decrease in the number of lesions (53.9%) compared to topical ivermectin (55.2%) and permethrin (19%) at the first follow-up. Long-Term Effects: By the fourth week, the combination therapy maintained its efficacy with only 15.8% of patients reporting severe itching,
						significantly lower than

								the other treatment
								groups.
Al-Asadi et al 2023	Iraq	RCT	study's findings suggest that combining topical and oral ivermectin provides enhanced efficacy in managing uncomplicate d scabies compared to permethrin or topical ivermectin alone. The significant reduction in itching and lesion count observed with combination therapy highlights its potential as a more effective treatment option for scabies	University of Basrah, Basrah, Iraq	study aimed to evaluate the efficacy and safety of different treatments for uncomplicated scabies lesions. Outcome measures included:  Severity of itching reduction Reduction in the number of scabietic lesions Patient-reported adverse events and safety profile of treatments	Overall, the combination of topical and oral ivermectin was deemed safe and well-tolerated, with fewer adverse events reported compared to other treatment modalities.	236	Treatment Efficacy: The combination group (topical and oral ivermectin) demonstrated superior efficacy compared to permethrin and topical ivermectin alone. Reduction in Itching: At the first week, the combination treatment group showed a significant decrease in severity of itching (77.6%) compared to topical ivermectin (61.8%) and permethrin (8.3%). Reduction in Lesions: Similarly, the combination treatment group had a significant reduction in the number of lesions (53.9%) compared to topical ivermectin (55.2%) and permethrin (19%). Long-Term Efficacy: By the fourth week, only 15.8% of patients in the combination treatment group reported severe itching, significantly lower than the other groups.
Manjhi et al 2014	India	RCT	The study suggests that oral ivermectin can be considered as an alternative to topical scabicidal treatments, especially in	IGIMS, Sheikhpur a, Patna, Bihar, India	Efficacy was measured based on improvement in severity of pruritus and lesion severity at 1-week and 6-week follow-ups. The percentage improvement in these parameters was used to	Oral ivermectin was well- tolerated and did not cause skin irritation or central nervous system side effects since it does not cross the blood-	240	Oral ivermectin (200 μg/kg body weight) and topical permethrin (5% cream) demonstrated similar efficacy in treating scabies, with both showing significant improvement in severity of pruritus (85% and 90% respectively) and lesion

						_		
			cases where topical therapies are poorly tolerated or potentially irritating. Topical permethrin remains a standard and effective treatment for scabies, demonstratin g slightly higher efficacy compared to other topical options. The findings support the use of oral ivermectin due to its ease of administratio n and favorable safety profile, particularly in patients who may have issues with compliance or skin sensitivity to topical agents.		compare the effectiveness of different treatment modalities	brain barrier. Topical treatments (permethrin, GBHC, BB lotion) may cause local skin irritation and discomfort, which could affect compliance.		severity (80% and 88.33% respectively) at follow-up. Topical permethrin was more effective than topical gamma benzene hexachloride (GBHC) lotion (1%) and topical benzyl benzoate (BB) lotion (25%).
Sattar et al 2023	Pakistan	RCT	The study findings align with prior research on scabies treatments. Challenges in application	Departme nt of Dermatol ogy, Pak Emirates Military Hospital, Rawalpind	Participants underwent skin examinations and were randomly assigned to receive either 5% permethrin	Both permethrin cream and oral ivermectin were generally well-tolerated.	60	There was no significant difference in scabies cure rates between permethrin (73.3% efficacy) and ivermectin (70% efficacy) groups (P=0.775). Notably,
			Challenges in	Hospital,	receive either 5%	generally well-		efficacy) groups

			resistance could impact treatment efficacy. Further investigation s are needed, especially in pediatric populations, to optimize treatment strategies and address safety concern		ivermectin. Efficacy was assessed at 2 weeks post- treatment based on clinical improvement and negative microscopy.	relief was provided with hydroxyzine. No serious adverse events were reported.		remained symptomatic after treatment, possibly due to drug resistance.
Verma et al 2020	India	RCT		Rohilkhan d Medical College and Hospital	Significant improvement in scabies severity was seen at the 1st and 2nd followâ€'up in both groups (P < 0.001). The cure rate was 2%, 96.1%, and 100% in Group A, while 68%, 98%, and 100% in Group B at each followâ€'up,	Adverse events were reported nine and 12 times in Groups A and B,	106	Two applications of 0.5% topical IVM cream and single dose of oral IVM are equally efficacious and safe for the treatment of scabies at the end of the 2nd and 4th weeks
Lake et al 2022	Solomo n Islands	Cross secti onal study		aTropical Diseases Research Group, Murdoch Childrenâ €™S Research Institute, Melbourn e, Victoria, Australia;	Dermatology Life Quality Index (DLQI) and Children's Dermatology Life Quality Index (CDLQI) to assess the impact of scabies on Health-Related Quality of Life (HRQOL) in adults and children. Both indices demonstrated specificity in populations affected by scabies, with increased impact		105 1 + 604	scabies has a measurable impact on HRQoL in the Solomon Islands, affecting various domains such as symptoms, school/work performance, and daily activities. Notably, the study highlights the cultural acceptance of scabies within the community, potentially influencing reporting and perceptions of disease impact. The study underscores the need for improved interventions and culturally tailored

Ständer		The ctudy	University	correlating with disease severity.		measures to address scabies' burden effectively in endemic regions.
et al 2021		The study provides valuable insights into the pathophysiol ogy of scabies-related itch, highlighting the role of non-histaminergic mechanisms in mediating itch sensations. Identification of specific receptors and markers associated with scabies itch opens up new avenues for developing targeted therapies aimed at alleviating itch symptoms.	University of Lübeck, Lübeck, Germany,	Outcome measures included the assessment of elevated levels of non- histaminergic mediators of itch (TRPV1, TRPA1, PAR-2, tryptase+ cells) in scabies- infected skin compared to healthy controls. Complications related to scabies itch, such as disruptions in the skin barrier and increased susceptibility to bacterial infections, were also examined as outcomes.		Specific receptors and markers (TRPV1, TRPA1, PAR-2, and tryptase+ cells) associated with non-histaminergic itch were found to be upregulated in scabies-infected skin, suggesting these as potential therapeutic targets for managing scabies-related itch. Complications linked to scabies itch were discussed, highlighting the role of immune responses towards mites and mite-derived complement inhibitors in promoting bacterial infections and disrupting the skin barrier.
KoçY?ld?r? m et al 2023	Cross secti onal study	The study underscores the significant impact of scabies on the QoL of affected individuals, highlighting the need for comprehensi ve management	Departme nt of Dermatol ogy and Venereolo gy, UÅŸak University Training and Research Hospital, UÅŸak, Turkey	The impact of scabies on QoL was assessed using the Dermatology Life Quality Index (DLQI), which measures how much a skin condition affects the patient's life. Depression and anxiety levels were evaluated	85	The study assessed the impact of scabies on the quality of life (QoL) of adult patients and evaluated the relationship between scabies-related impairment in QoL and levels of depression and anxiety. Results showed that scabies significantly affects the QoL of patients, with 72.2% experiencing

			strategies that consider		using the Beck Depression Scale			moderate to extremely large impacts. The
			both the		(BDS) and Beck			duration and severity
			physical and		Anxiety Scale			of the disease, as well
					•			as the number of
			psychological		(BAS),			
			aspects of		respectively.			treatments received,
			the disease.					correlated positively
			The positive					with the degree of QoL
			correlations					impairment.
			observed					Additionally, there was
			between disease					a positive correlation between
								depression/anxiety
			severity, treatment					levels and the overall
			history, and					impact of scabies on
			QoL					QoL.
			impairment					QUL.
			further					
			emphasize					
			the					
			importance					
			of timely and					
			effective					
			interventions					
Amoako et	Ghana			Kumasi	Knowledge and			Participants with active
al 2023				Centre for	beliefs about			or past scabies
				Collaborat	scabies causation			exhibited
				ive	and risk factors.			misconceptions about
				Research	Perceptions			the causes and risk
				in Tropical	towards			factors, attributing
				Medicine,	stigmatization			scabies to poor
				Kwame	and			hygiene, traditional
				Nkrumah	consequences of			beliefs, heredity, and
				University	scabies in daily			drinking water.
				of Science	life.			Beliefs in supernatural
				and	Treatment-			causes like witchcraft
				Technolog	seeking			or curses contributed
				y, Kumasi,	behaviors and			to delayed care-seeking
				Ghana,	delays in care.			behavior and perceived
								limited disease
								severity.
								Delayed diagnosis and
								treatment were
								common, with a
								median delay of 21
								days from symptom
								onset to seeking healthcare.
								nealthcare. Scabies were
								associated with stigma,
	1	l	i	İ	İ	1	1	associated with Stigma.

								health consequences, and loss of productivity in affected individuals.
Wootton et	Ghana		The study		The study aimed		128	Individuals with scabies
al 2018			highlights the		to assess beliefs,			in central Ghana often
			importance		attitudes, and			delay seeking care due
			of addressing		practices towards			to beliefs and
			community		scabies in central			perceptions about the
			beliefs and		Ghana.			disease, such as
			attitudes		Specifically, the			associating it with
			towards		study examined			curses or witchcraft.
			scabies to		knowledge about			The delay in seeking
			improve		scabies causes			care is influenced by
			care-seeking		and risk factors,			limited understanding
			behavior and		perceptions of			of the severity and
			control		stigmatization			transmission of scabies.
			measures.		and			Scabies is perceived to
			Health		consequences,			have health
			education is		and treatment			consequences, stigma,
			essential to		practices.			and affects productivity
			enhance					in affected individuals.
			knowledge					Early diagnosis and
			and					effective treatment can
			awareness of					help dispel negative
			scabies					perceptions and
			among					promote care-seeking
			communitie					behaviors.
Nair et al	•	•	•		The study aimed	•	102	Demographics: The
2016					to evaluate			study included 102
					various			newly diagnosed
					demographic			scabies patients, with a
					details, clinical			slightly higher
					features, and			prevalence in males
					quality of life			(50.98%) compared to
					among patients with scabies.			females.
					Specific outcome			Age Group: The most affected age group was
					measures			21-40 years,
					included:			representing 44.11% of
					iliciadea.			patients.
					Demographic			Occupation: Students
					details: Age, sex,			were predominantly
					occupation,			affected (41.17%),
					education,			followed by
					socioeconomic			housewives (20.58%).
					status.			Clinical Features:
					Clinical profile:			Papules were the most
					Presenting			common lesion
					complaints, past			observed (84.3%),
					history, family			followed by
					history, and			excoriations (82.3%).
L	1	1	1	1		i		(2=.0,0).


		specific clinical features of scabies lesions. Quality of life assessment: Impact of scabies on daily life activities, work, sleep, and psychosocial well-being using a structured questionnaire.		Quality of Life: More than half of adult patients (51.6%) reported a mild effect on quality of life, while the majority of children (62.5%) reported minimal impact.
Urban et al 2021	The study underscores the significance of using DALYs to assess and prioritize skin diseases in Asian populations. By correlating DALYs with socioeconom ic indicators, the research highlights disparities in disease burden based on a country's economic status. The findings suggest that resources and interventions should be tailored to address specific skin disease patterns prevalent in different	The study analyzed Disability- Adjusted Life Years (DALYs) attributed to skin diseases across 50 Asian countries from 1990 to 2017. DALYs were used as a metric to quantify the burden of disease, considering age- standardized rates and comparing them with country- level socioeconomic indicators such as the sociodemographi c index and gross domestic product per capita.	50 countri es	some Asian countries had higher or lower age-standardized Disability-Adjusted Life Year (DALY) rates for skin diseases than expected based on their socioeconomic status.  High-income Asian countries had a significant burden of inflammatory skin conditions, such as acne, alopecia areata, atopic dermatitis, contact dermatitis, decubitus ulcers, psoriasis, pruritus, and seborrheic dermatitis.  On the other hand, low-income Asian countries experienced a greater burden of infectious skin diseases.

	socioeconom			
	ic contexts			
	within Asia			
	within Asia			_

### **Results-**

# 3.1. Comprehensive literature search

The selection procedure of all records received through the literature search is illustrated in Figure 1. A total of 242 records were screened, of which 168 articles were from Cochrane Central and 73 articles from PubMed. Of these, 16 records were removed after being found duplicated. 226 articles were screened for title and abstract and 96 articles were removed for not matching criteria. 130 reports were sought for retrieval and 70 of them were not retrieved due to lack of text. 61 articles were assessed for eligibility, out of which 31 articles were removed due to various reasons. Finally, 29 studies are included in this review. The Prisma Flow chart is given below:






Figure 1: PRISMA flow diagram of the selection process of records

### 3.2. Risk of Bias of Included Studies

Overall, the studies were rated low to moderate risk of bias. None of the studies were rated as a high risk of bias. All types of bias (Confounding, selection, exposure assessment, outcome measurement, missing data, and selective reporting) were graded as low to moderate only.




Fig: 1: Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)
Al-Asadi,	•	•	?	•	•	•
Alipour,	•	•	?	•	•	•
Amoako	•	•	?	•	•	?
Anissa,	•	•	?	•	?	•
Behera,	?	•	•	•	?	•
Hardy,	•	•	•	?	•	?
Illyas,	?	•	•	•	?	•
KoçYıldırım 2023,	?	•	•	•	?	•
Lake 2020,	?	•	•	•	•	•
Lake 2022,	•	•	•	•	•	?
Manjhi,	•	•	•	?	?	•
Marina,	•	?	•	•	•	•
Marks 2019,	•	•	•	?	•	?
Marks 2020,	•	•	•	•	?	?
Matthewman,	•	•	•	?	•	•
Meyersburg 2023,	?	•	•	•	•	•
Meyersburg 2024,	•	•	?	•	•	•
Nair	?	•	?	•	•	•
Romani,	•	•	•	•	•	?
Sattar,	•	•	•	?	•	•
Shaheen,	•	•	?	?	•	•
Stander,	•	?	•	•	?	•
Sungkar,	•	?	•	•	?	•
Susanna J,	•	•	?	•	•	•
Thomas,	•	•	?	•	•	•
Urban	•	•	•	•	•	?
Usman,	•	•	?	•	?	•
Verma,	•	•	•	•	?	?
Wootton	•	•	•	?	?	•

Fig:2: Risk of bias summary: review authors' judgments about each risk of bias item for each included study.

## 3.3. General study characteristics

The study involved a significant sample size, comprising data from 40,343 individuals across 20 villages, 6 communities, and 50 countries. This extensive geographic coverage enabled a broad analysis of treatment regimens. The treatment durations studied ranged from 4 weeks to 12 months, reflecting the real-world variability in how long individuals receive treatments. Within this scope, the study design incorporated 22 randomized controlled trials (RCTs) and 2 cross-sectional studies.

Table 1 gives an overview of the 29 studies included in the systematic review. The publication years ranged from 2014 to 2024.

3.4. Conceptualization, operationalization, rationale, and discussion of results All 22 studies demonstrated a significant impact of scabies diagnosis and quality of life on the participants. Koç Yıldırım S et al. observed a moderate to severe effect on the quality of life [38], while Khaled Seetan et al. identified a significant association between scabies and anxiety/depression, further compromising the quality of life [39].

In terms of treatment and management, permethrin was found to be the most effective in treating scabies and associated sequelae. It targets eggs, lice, and mites by working on sodium transport across neuronal membranes in arthropods, causing depolarization. This results in the respiratory paralysis of the affected arthropod. Abdel-Raheem et al. noted its high acceptability due to rapid action, although at a higher cost per case. Alternatively, Ivermectin demonstrated efficacy and acceptability rates of 84% and 96%, respectively, at a lower cost compared to permethrin. Benzyl benzoate, though cheaper, exhibited lower efficacy rates. Sulphur ointment, despite being the most expensive option, provided the least favorable outcomes [40]. Certain studies have reported that both permethrin and ivermectin regimens are equally efficacious and well-tolerated in scabies [41].

When comparing permethrin to other alternatives, Abolfazl et al. found that two applications of permethrin 5% cream matched the efficacy of single applications of crotamiton 10% cream at the 2-week follow-up, with superior outcomes for permethrin at the 4-week follow-up. Similarly, Goldust et al. reported

significantly higher efficacy with permethrin 2.5% cream compared to Tenutex emulsion at the 4-week follow-up [42].

Given the developing resistance against Permethrin, Alipour et al. mentioned that Ivermectin can also treat scabies effectively. A single dose of ivermectin provided a cure rate of 61.9% at the 2-week follow-up, which increased to 78.5% at the 4-week follow-up after repeating the treatment [43]. The drug binds to glutamate-gated chloride channels common to invertebrate nerve and muscle cells. The binding pushes the channels open, which increases the flow of chloride ions and hyperpolarizes the cell membranes, paralyzing and killing the arthropod.

Alternatively, combining drugs also helped to prevent resistance. Michael Marks et al. suggested that co-administration of azithromycin with ivermectin led to similar decreases in scabies prevalence compared to ivermectin [44]. Alebiosu et al. reported that Toto ointment and soap are particularly efficacious in the management of scabies, suggesting that they can be included in the treatment regimen to prevent resistance. [45]

### Discussion

Scabies remains a significant global health issue, particularly in resourcelimited settings. Despite its prevalence and impact on individuals and communities, scabies often receive inadequate attention in healthcare settings and research agendas. Scabies affects individuals of all ages and socioeconomic backgrounds, with a higher prevalence observed in overcrowded areas. The burden of scabies extends beyond physical discomfort, impacting quality of life, mental health, and economic productivity. Thus, it is imperative to diagnose scabies early and initiate treatment as soon as possible.

Diagnosis can be made through a thorough elicitation of history and clinical examination. A history of new, intense pruritus and dermatitis raises suspicion for diagnosis, which can be confirmed by skin scrapings and microscopic demonstration of scabies mites, eggs, or fecal matter. [46] Recent advances in diagnosis include PCR assays to screen for scabies mite DNA. Dermatoscopy, which is a non-invasive imaging technique, has shown promising results in this regard. Other non-invasive procedures, including video dermatoscopy, reflectance confocal microscopy, and optical coherence tomography, have demonstrated improved efficacy in the diagnosis of scabies. [47]

Difficulty in diagnosis can arise in many situations, as scabies present with intense itching and characteristic burrows, but these signs may be absent in certain individuals, leading to misdiagnosis or delayed diagnosis. The similarity of symptoms with other skin conditions like eczema or dermatitis complicates accurate diagnosis, especially in settings where diagnostic tools are limited.

According to the European Academy of Dermatology and Venereology, recommended treatments are Permethrin 5% cream, oral ivermectin, and benzyl benzoate 25% lotion. Alternative treatment modalities are Malathion 0.5% aqueous solution, ivermectin 1% lotion, and sulfur 6-33% cream, ointment, or lotion.

Crusted scabies therapy requires topical scabicide or oral ivermectin. Mass treatments of large populations with endemic disease can be done with a single dose of ivermectin at 200 mg/kg body weight. Any or all sexual partners for the past two months must also be treated.

The STI workup of affected individuals is indicated. Patients and close contacts must abstain from sexual contact until the completion of treatment and should observe strict personal hygiene when living in crowded spaces. [48] Known causes of treatment failure include improper application of external agents, failure of repeated treatment with ivermectin, incomplete decontamination of belongings, failure to treat people in close contact simultaneously, and other risk factors for the patient. Some documentation suggests a poor response to permethrin due to the resistance of scabies mites. [46]

Recent advancements in the treatment of scabies are explored, including new topical ointments and oral regimens. There are trials to bring in new drugs to avoid resistance to drug therapy. Moxidectin is a new drug that is undergoing clinical trials to replace permethrin in regions with high resistance. [46]

Challenges in treatment include resistance to conventional chemotherapy due to overreliance on standard treatments like permethrin or ivermectin, reducing treatment efficacy. Treating scabies in certain demographics, such as infants, pregnant women, or immunocompromised individuals, requires careful consideration due to safety concerns associated with conventional therapies.

Since scabies is considered a significant health problem worldwide, intensive research looks into aspects of the biology of Sarcoptes scabiei and host-parasite interactions. However, the practicality of conducting these trials is limited due to the inability to maintain mites in vitro and the limited access to infective material. At present, research is focused on the initial characterization of molecules of interest to improve diagnosis and vaccines and eliminate drug resistance. Recent developments anticipate combining animal models and nextgeneration technologies to create new strategies to prevent, diagnose, and treat scabies, ultimately improving skin health in patients. [49]

The incorporation of telemedicine and ethical AI in medicine can also improve the diagnosis and early treatment of scabies in patients. Exploration of host factors influencing scabies susceptibility and treatment response to develop personalized treatment approaches. Utilization of machine learning algorithms

for early detection of scabies outbreaks, predicting treatment responses, and identifying genetic markers associated with scabies resistance can be areas of potential research in the future.

To improve patient outcomes in scabies, certain comprehensive strategies, like early diagnosis and treatment compliance, should be followed. A prompt diagnosis of scabies can cut down on transmission and prevent further complications. Consistent treatment ensures the complete eradication of the disease and prevents resistance. Educating patients about proper hygiene, transmission, treatment compliance, and prevention of scabies plays a vital role in reducing the global burden of scabies. Healthcare individuals must be equipped with the latest diagnostic technologies and knowledge of the latest treatment guidelines to improve patient outcomes. Resistant cases must be addressed at the earliest possible time to prevent further transmission. Finally, effective research focusing on developing newer diagnostic and treatment modalities must be conducted for improved patient outcomes.

#### **Conclusion:**

Our study concluded that scabies is a debilitating disease with a significant impact on quality of life. It was found that permethrin was the most effective treatment modality and was widely accepted by all patients. It also has a rapid onset of action; however, the higher cost per patient may limit its use in every region. While Ivermectin is a drug that is better used in cases of permethrinresistant scabies, it has a lower cost and can be used as a first-line drug. Among all the drugs, benzyl benzoate is the cheapest, and sulfur ointments are the most expensive. The combination of drugs has yielded significant positive results and should be explored more. Recent advances include efforts to minimize drug resistance and increase the efficacy of existing drugs. With drugs like moxidectin undergoing trials for usage in areas of high resistance [46] and other drugs for topical use, hope for the elimination of this disease ensues. With studies describing the impairment of QoL as being 'very large' [50], the need to address the symptoms and provide complete and effective care is rising. There are multiple studies on the quality of life, but these are very scattered and region-specific. A global study must be done to evaluate children and adults from all over the world, and interventions should be implemented at a grassroots level. The effect of these interventions should be studied concerning improvement in QoL. Interventions should be both 'patient-centered' to allow a rapid cure of disease with minimal psychosocial effect in the person's daily life. Drugs can be developed that are both anti-parasite and prevent secondary bacterial infections.

Scabies was declared a neglected tropical disease [NTD] in 2017 by the WHO [51]. Since then, multiple programs have been set forth to target the reduction of the prevalence of these NTDs and promote access to rapid-acting and cost-

effective medications to treat this disease. The World Scabies Program [52] is another worldwide project that aims to spread awareness about the health implications of this disease and promote groundbreaking translational research to enhance the development of drugs and treatment strategies. An urgent global collaboration is key to the control and management of this disease. Surveillance and interventional programs must be conducted at every level of the community, starting from the smallest villages and rural areas to the state and country as a whole. Control requires an interdisciplinary approach, involving doctors, community workers, state administration, psychologists, and epidemiologists, among other stakeholders.

### **References:**

- 1. Salavastru CM, Chosidow O, Boffa MJ, Janier M, Tiplica GS. European guideline for the management of scabies. J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1248–53.
- 2. Micali G, Lacarrubba F, Verzì AE, Chosidow O, Schwartz RA. Scabies: Advances in Noninvasive Diagnosis. Vinetz JM, editor. PLoS Negl Trop Dis. 2016 Jun 16;10(6):e0004691.
- 3. Paudel S, Pudasaini P, Adhikari S, Pradhan MB, Shekhar Babu KC. Quality of life in patients with scabies: A cross-sectional study using Dermatology Life Quality Index (DLQI) questionnaire. JEADV Clin Pract. 2023 Jun;2(2):399–403.
- 4. Koç Yıldırım S, Demirel Öğüt N, Erbağcı E, Öğüt Ç. Scabies Affects Quality of Life in Correlation with Depression and Anxiety. Dermatol Pract Concept. 2023 Apr 29;e2023144.
- 5. Marks M, Toloka H, Baker C, Kositz C, Asugeni J, Puiahi E, et al. Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo. Clin Infect Dis. 2019 Mar 5;68(6):927–33.
- 6. Alipour H, Goldust M. The efficacy of oral ivermectin vs. sulfur 10% ointment for the treatment of scabies. Ann Parasitol. 2015;61(2):79–84.
- 7. Goldust M, Rezaee E, Raghifar R, Hemayat S. Treatment of scabies: the topical ivermectin vs. permethrin 2.5% cream. Ann Parasitol. 2013;59(2):79–84.

- 8. Abdel-Raheem TA, Méabed EMH, Nasef GA, Abdel Wahed WY, Rohaim RMA. Efficacy, acceptability and cost effectiveness of four therapeutic agents for treatment of scabies. J Dermatol Treat. 2016 Sep 2;27(5):473–9.
- 9. Meyersburg D, Hoellwerth M, Brandlmaier M, Handisurya A, Kaiser A, Prodinger C, et al. Comparison of topical permethrin 5% vs. benzyl benzoate 25% treatment in scabies: a double-blinded randomized controlled trial. 2024;190(4):486-491-. Available from:
- 10. Hardy M, Samuela J, Kama M, Tuicakau M, Romani L, Whitfeld MJ, et al. Community control strategies for scabies: a cluster randomised noninferiority trial. 2021;18(11):e1003849-. Available from:
- 11. Alipour H, Goldust M. The efficacy of oral ivermectin vs. sulfur 10% ointment for the treatment of scabies. 2015;61(2):79-84-. Available from:
- 12. Marina A, Menaldi SL, Novianto E, Widaty S. Efficacy of 5% permethrin-2% fusidic acid cream compared to 5% permethrin-placebo in the treatment of impetiginized scabies. 2022;16(6):1045-1054-. Available from:
- Romani L, Marks M, Sokana O, Nasi T, Kamoriki B, Cordell B, et al. 13. Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. 2019;19(5):510-518-. Available from:
- 14. Illyas M, Shahzad A, Siddiqui S, Awais M, Qayyum M, Azfar NA. Comparison of efficacy of oral ivermectin and topical permethrin 5% in the treatment of scabies. 2023;33(1):123-131-. Available from:
- 15. ACTRN12618001086257. Regimens of Ivermectin for Scabies Elimination: a cluster randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy. 2018; Available from:

- Matthewman J, Manego RZ, Dimessa Mbadinga LB, Šinkovec H. 16. Völker K, Akinosho M, et al. A randomized controlled trial comparing the effectiveness of individual versus household treatment for Scabies in Lambaréné, Gabon. 2020;14(6):e0008423-. Available from:
- 17. Lake SJ, Phelan SL, Engelman D, Sokana O, Nasi T, Boara D, et al. Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study). 2020;10(8):e037305-. Available from:
- 18. Sungkar S, Agustin T, Menaldi SL, Fuady A, Hergutanto, Angkasa H, et al. Effectiveness of permethrin standard and modified methods in scabies treatment. 2014;23(2):93-98-.
- 19. Meyersburg D, Welponer T, Kaiser A, Selhofer S, Tatarski R, Handisurya A, et al. Comparison of topical benzyl benzoate vs. oral ivermectin in treating scabies: a randomized study. 2023;37(1):160-165-.
- 20. Behera P, Munshi H, Kalkonde Y, Deshmukh M, Bang A. Control of scabies in a tribal community using mass screening and treatment with oral ivermectin -A cluster randomized controlled trial in Gadchiroli, India. 2021;15(4):e0009330-.
- 21. Marks M, Gwyn S, Toloka H, Kositz C, Asugeni J, Asugeni R, et al. Impact of Community Treatment with Ivermectin for the Control of Scabies on the Prevalence of Antibodies to Strongyloides stercoralis in Children. 2020;71(12):3226-3228-.
- 22. Marks M, Toloka H, Baker C, Kositz C, Asugeni J, Puiahi E, et al. Randomized Trial of Community Treatment With Azithromycin and Ivermectin

Mass Drug Administration for Control of Scabies and Impetigo. 2019;68(6):927-933-.

- 23. Thomas J, Davey R, Peterson GM, Carson C, Walton SF, Spelman T, et al. Treatment of scabies using a tea tree oil-based gel formulation in Australian Aboriginal children: protocol for a randomised controlled trial. 2018;8(5):e018507-.
- 24. Anissa L, Indriatmi W, Wibawa LP, Widaty S. Efficacy and side effects of Blacksoap® as adjuvant therapy of scabies: a randomized control trial. 2022;31(2):102-107-.
- 25. Usman A, Shehzad A, Shahid M, Saleem Z, Khawaja A, Abeer. Comparison between efficacy of topical 1% ivermectin and topical 5% permethrin in the treatment of scabies. 2021;31(4):633-636-.
- 26. Shaheen A, Usman S, Mirbahar AM, Hameed RMH. Comparing the two treatment regimes for scabies, topical permethrin 5% with oral ivermectin. 2017;28(3):15-18-. Available from:
- 27. Al-Asadi ZA, Al-Hamdi KI, Ahmed JH. Effectiveness of Combined Oral and Topical Ivermectin Compared to Topical Treatments in Patients with Scabies. 2023;13(1):101-104-. Available from:
- 28. Manjhi PK, Sinha RI, Kumar M, Sinha KI. Comparative study of efficacy of oral ivermectin versus some topical antiscabies drugs in the treatment of scabies. 2014;8(9):HC01-4-.
- 29. Sattar RMT, Malik NA, Riaz U, Khalid AA, Jabin I, Warraich FK. Comparison of Efficacy of Single Application Topical 5% Permethrin versus Single Dose Oral Ivermectin in the Treatment of Scabies. 2023;17(10):18-20-.

- 30. Verma S, Ahsan M. Comparison of topical ivermectin and oral ivermectin in the treatment of human scabies: a randomized controlled trial. 2020;11(4):134-139
- 31. Lake SJ, Engelman D, Sokana O, Nasi T, Boara D, Marks M, et al. Healthrelated quality of life impact of scabies in the Solomon Islands. 2022;116(2):148-156-.
- 32. Ständer S. Itch in Scabies-What Do We Know? Front Med (Lausanne). 2021;8:628392.
- 33. Koç Yıldırım S, Demirel Öğüt N, Erbağcı E, Öğüt Ç. Scabies Affects Quality of Life in Correlation with Depression and Anxiety. Dermatol Pract Concept. Published online April 1, 2023. doi:10.5826/dpc.1302a144
- 34. Amoako YA, S van RL, Oppong MN, Amoako KO, Abass KM, Anim BA, et al. Beliefs, attitudes and practices towards scabies in central Ghana. PLoS Negl Trop Dis. 2023;17(2):e0011175-.
- 35. Wootton CI, Bell S, Philavanh A, Phommachack K, Soukavong M, Kidoikhammouan S, et al. Assessing skin disease and associated health-related quality of life in a rural Lao community. BMC Dermatol. 2018;18(1):11.
- 36. Nair PA, Vora R V, Jivani NB, Gandhi SS. A Study of Clinical Profile and Quality of Life in Patients with Scabies at a Rural Tertiary Care Centre. J Clin Diagn Res. 2016;10(10):WC01-5.
- 37. Urban K, Chu S, Giesey RL, Mehrmal S, Uppal P, Delost ME, et al. Burden of skin disease and associated socioeconomic status in Asia: A crosssectional analysis from the Global Burden of Disease Study 1990-2017. JAAD Int. 2021;2:40-50.

- 38. Koç Yıldırım S, Demirel Öğüt N, Erbağcı E, Öğüt Ç. Scabies Affects Quality of Life in Correlation with Depression and Anxiety. Dermatol Pract Concept. 2023 Apr 1;13(2):e2023144. doi: 10.5826/dpc.1302a144. Epub ahead of print. PMID: 37196304; PMCID: PMC10188156.
- 39. Seetan, Khaled, Balqis Abusohyon Almu'atasim Khamees, Hedaia Mohammad Alrababah, Furat Khasawneh, Ahmad Mowafaq Albataineh, Ali Zaid Mahajnah, and Rahaf Al-Showaiter. "SCABIES IS ASSOCIATED WITH MORE ANXIETY, DEPRESSION, AND IMPAIRED QUALITY OF LIFE: A CROSS-SECTIONAL COMPARATIVE STUDY." Journal of Pharmaceutical Negative Results (2022): 6314-6320.
- 40. Abdel-Raheem TA, Méabed EM, Nasef GA, Abdel Wahed WY, Rohaim RM. Efficacy, acceptability and cost effectiveness of four therapeutic agents for treatment of scabies. J Dermatolog Treat. 2016 Oct;27(5):473-9. doi: 10.3109/09546634.2016.1151855. Epub 2016 Mar 30. PMID: 27027929.
- 41. Ranjkesh MR, Naghili B, Goldust M, Rezaee E. The efficacy of permethrin 5% vs. oral ivermectin for the treatment of scabies. Ann Parasitol. 2013;59(4):189-94. PMID: 24791346.
- 42. Goldust M, Rezaee E, Raghifar R, Hemayat S. Treatment of scabies: the topical ivermectin vs. permethrin 2.5% cream. Ann Parasitol. 2013;59(2):79-84. PMID: 24171301.
- 43. Alipour H, Goldust M. The efficacy of oral ivermectin vs. sulfur 10% ointment for the treatment of scabies. Ann Parasitol. 2015;61(2):79-84. PMID: 26342502.
- 44. Marks M, Toloka H, Baker C, Kositz C, Asugeni J, Puiahi E, Asugeni R, Azzopardi K, Diau J, Kaldor JM, Romani L, Redman-MacLaren M, MacLaren D, Solomon AW, Mabey DCW, Steer AC. Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo. Clin Infect Dis. 2019 Mar 5;68(6):927-933. doi: 10.1093/cid/ciy574. PMID: 29985978; PMCID: PMC6399435.

- 45. Alebiosu CO, Ogunledun A, Ogunleye DS. A report of clinical trial conducted on Toto ointment and soap products. J Natl Med Assoc. 2003 Jan;95(1):95-105. PMID: 12656456; PMCID: PMC2594367.
- 46. Salavastru CM, Chosidow O, Boffa MJ, Janier M, Tiplica GS. European guideline for the management of scabies. J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1248-1253. doi: 10.1111/jdv.14351. Epub 2017 Jun 22. PMID: 28639722
- 47. Sunderkötter C, Wohlrab J, Hamm H. Scabies: Epidemiology, Diagnosis, and Treatment. Dtsch Arztebl Int. 2021 Oct 15;118(41):695-704. doi: 10.3238/arztebl.m2021.0296. PMID: 34615594; PMCID: PMC8743988.
- 48.Micali G, Lacarrubba F, Verzì AE, Chosidow O, Schwartz RA. Scabies: Advances in Noninvasive Diagnosis. PLoS Negl Trop Dis. 2016 Jun 16;10(6):e0004691. doi: 10.1371/journal.pntd.0004691. PMID: 27311065; PMCID: PMC4911127.
- 49. Mounsey KE, McCarthy JS, Walton SF. Scratching the itch: new tools to advance understanding of scabies. Trends Parasitol. 2013 Jan;29(1):35-42. doi: 10.1016/j.pt.2012.09.006. Epub 2012 Oct 19. PMID: 23088958.
- 50. Paudel S, Pudasaini P, Adhikari S, Pradhan M, Babu KCS. Quality of life in patients with scabies: A cross-sectional study using Dermatology Life Quality Index (DLQI) questionnaire. JEADV Clinical Practice. 2023;2(2):399-403. doi:10.1002/jvc2.127
- 51. World Health Organization: WHO, World Health Organization: WHO. Scabies. Published May 31, 2023. <a href="https://www.who.int/news-room/fact-sheets/detail/scabies">https://www.who.int/news-room/fact-sheets/detail/scabies</a>
- 52. Home World Scabies program. https://www.worldscabiesprogram.org/